Quoin Pharmaceuticals, LTD 8-K filings

Quoin Pharmaceuticals announced Japan's MHLW granted Orphan Drug Designation for QRX003 lotion (4%) for Netherton Syndrome, a rare genetic skin disorder.

Quoin Pharmaceuticals announced first quarter 2026 financial results, highlighting significant regulatory progress for QRX003 in Netherton Syndrome and advancements in its QRX009 platform.

Quoin Pharmaceuticals announced its Q4 and full-year 2025 financial results, highlighted by a significant private placement financing and accelerated regulatory pathways for its lead rare disease drug, QRX003.

Quoin Pharmaceuticals has applied for Breakthrough Medicine Designation with the SFDA for QRX003, its Netherton Syndrome treatment, potentially accelerating patient access in Saudi Arabia.

Quoin Pharmaceuticals Ltd. has approved the final forms of award agreements for stock options under its 2025 Equity Incentive Plan for directors and executive officers.

Quoin Pharmaceuticals successfully achieved target loading concentrations for two topical rapamycin delivery technologies, advancing clinical development for rare diseases.

Quoin Pharmaceuticals announced its third quarter 2025 financial results and a corporate update, highlighting a significant capital raise, clinical advancements for QRX003, and a new CFO appointment.

Quoin Pharmaceuticals Ltd. announced that the U.S. FDA granted Orphan Drug Designation to its lead product candidate, QRX003, for Netherton Syndrome, following a similar designation from the EMA.

Quoin Pharmaceuticals Ltd. announced a private placement raising $16.6 million upfront, with potential for up to $88.0 million more from warrant exercises, to fund operations into 2027.

Quoin Pharmaceuticals Ltd. finalized a separation agreement with former Chief Financial Officer Gordon Dunn, including a $433,620 severance and a $108,405 bonus.

Quoin Pharmaceuticals announced the appointment of Sally Lawlor as its new Chief Financial Officer and shareholder approval to significantly increase authorized ordinary share capital.

Quoin Pharmaceuticals reports significant clinical and regulatory advancements for QRX003 in rare skin diseases, alongside increased net loss in Q2 2025.

Quoin Pharmaceuticals Ltd. announced a mutual separation agreement with Chief Financial Officer Gordon Dunn, who will remain in his role until a successor is appointed.

Quoin Pharmaceuticals Ltd. announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation for its lead asset, QRX003, for the treatment of Netherton Syndrome.

Quoin Pharmaceuticals Ltd. has announced its 2025 Annual General Meeting of Shareholders will be held on August 21, 2025, necessitating revised deadlines for shareholder proposals due to the accelerated schedule.

Quoin Pharmaceuticals Ltd. announced the approval of 2024 annual cash bonuses for its CEO, Dr. Michael Myers, and COO, Ms. Denise Carter, totaling $331,238 and $264,640 respectively.

Quoin Pharmaceuticals Ltd. announced FDA clearance to initiate a second pivotal clinical study for its lead product QRX003 in Netherton Syndrome, aiming for a comprehensive data package to support broad regulatory approval.

Quoin Pharmaceuticals has been granted Orphan Drug Designation in Europe by the European Medicines Agency (EMA) for its lead product QRX003 in Netherton Syndrome, potentially granting 10 years of market exclusivity upon approval.

Quoin Pharmaceuticals reports continued progress in Netherton Syndrome studies, positive clinical data, and first quarter 2025 financial results, including a net loss of $3.8 million.

Quoin Pharmaceuticals has received notification from Nasdaq that it has regained compliance with the minimum bid price requirement, resolving a prior compliance issue.

Quoin Pharmaceuticals implements a 1-for-35 reverse stock split of its American Depositary Shares (ADSs) to meet Nasdaq's minimum bid price requirement.

Quoin Pharmaceuticals is implementing a 1-for-20 reverse stock split of its American Depositary Shares (ADSs) to meet Nasdaq's minimum bid price requirement.

Quoin Pharmaceuticals reports highly positive clinical data from its ongoing Investigator Pediatric Netherton Syndrome (NS) study, showing sustained healing and improved quality of life for the patient.

Quoin Pharmaceuticals has replaced its independent registered public accounting firm from Marcum LLP to CBIZ CPAs, effective immediately on March 18, 2025.

Quoin Pharmaceuticals announces positive clinical trial results for QRX003 in Netherton Syndrome, along with financial results for the fourth quarter and full year 2024.

Quoin Pharmaceuticals reports highly positive clinical data from its pediatric Netherton Syndrome study, showing significant improvements with QRX003 treatment.

Quoin Pharmaceuticals initiates the NETHERTON NOW campaign to increase awareness and understanding of Netherton Syndrome, a severe genetic skin disorder.

Quoin Pharmaceuticals reports that the positive clinical effects of QRX003 in a Netherton Syndrome patient reversed four weeks after treatment cessation, reverting to baseline status.

Quoin Pharmaceuticals reported significant skin improvement in a pediatric Netherton Syndrome study after six weeks of treatment with QRX003, leading to whole-body application.

Quoin Pharmaceuticals reports significant improvements in a patient with Netherton Syndrome after 12 weeks of treatment with QRX003, showing positive results across multiple clinical endpoints.